GSK plc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of GSK plc Company

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

GSK plc Info



Ticker SymbolGSK

Company nameGSK plc

IPO dateMay 22, 1972

CEOMs. Deborah Waterhouse

Number of employees68629

Security typeOrdinary Share

Fiscal year-endMay 22

Address980 Great West Road

CityBRENTFORD

Stock exchangeLondon Stock Exchange

CountryUnited Kingdom

Postal codeTW8 9GS

Phone442080475000

Websitehttps://www.gsk.com/

Ticker SymbolGSK

IPO dateMay 22, 1972

CEOMs. Deborah Waterhouse

Company Executives of GSK plc



Name

Name/Position

Position

Shareholding

Change

Dr. Hal V. Barron, M.D.

Non-Executive Director

658.41K

+0.49%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

484.59K

+0.08%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

38.91K

+0.88%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

3.00K

+0.87%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

1.58K

+0.83%

Dr. Harry C. (Hal) Dietz

Independent Non-Executive Director, Scientific and Medical Expert

--

Mr. James Ford

Senior Vice President, Group General Counsel, Legal and Compliance

--

Ms. Sally Jackson

Senior Vice President - Global Communications and CEO Office

--

Dr. Tony Wood, Ph.D.

Chief Scientific Officer

--

Ms. Julie Brown

Chief Financial Officer, Executive Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Hal V. Barron, M.D.

Non-Executive Director

658.41K

+0.49%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

484.59K

+0.08%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

38.91K

+0.88%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

3.00K

+0.87%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

1.58K

+0.83%

Dr. Harry C. (Hal) Dietz

Independent Non-Executive Director, Scientific and Medical Expert

--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

No Data

By RegionUSD

Name

Revenue

Proportion

US

5.49B

51.53%

Rest of world

2.71B

25.44%

Europe

2.45B

23.03%

By Business

By Region

No Data

Shareholding Stats

Updated: Sun, Aug 17

Shareholders

Shareholder Types

Shareholders

Proportion

Dodge & Cox

3.88%

Fidelity Management & Research Company LLC

2.53%

Fisher Investments

1.54%

PRIMECAP Management Company

1.37%

JTC Employer Solutions Trusteee Ltd

0.72%

Other

89.96%

Shareholders

Proportion

Dodge & Cox

3.88%

Fidelity Management & Research Company LLC

2.53%

Fisher Investments

1.54%

PRIMECAP Management Company

1.37%

JTC Employer Solutions Trusteee Ltd

0.72%

Other

89.96%

Shareholder Types

Shareholders

Proportion

Investment Advisor

9.67%

Investment Advisor/Hedge Fund

7.36%

Research Firm

1.05%

Hedge Fund

0.82%

Bank and Trust

0.11%

Individual Investor

0.06%

Pension Fund

0.06%

Insurance Company

0.05%

Family Office

0.03%

Other

80.79%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

1447

387.77M

19.07%

-8.51M

2025Q2

1478

378.08M

18.54%

+5.70M

2025Q1

1494

378.46M

18.50%

+5.08M

2024Q4

1481

355.06M

17.14%

+27.38M

2024Q3

1472

319.97M

15.44%

-30.07M

2024Q2

1585

322.06M

15.54%

-29.11M

2024Q1

1617

318.91M

15.39%

-23.52M

2023Q4

1614

299.81M

14.57%

-35.71M

2023Q3

1570

293.92M

14.35%

-37.46M

2023Q2

1545

286.58M

13.99%

-41.88M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Dodge & Cox

78.76M

3.87%

+106.04K

+0.13%

Jun 30, 2025

Fidelity Management & Research Company LLC

51.48M

2.53%

+872.19K

+1.72%

Jun 30, 2025

Fisher Investments

31.34M

1.54%

+1.31M

+4.35%

Jun 30, 2025

PRIMECAP Management Company

27.73M

1.36%

+2.02M

+7.85%

Jun 30, 2025

JTC Employer Solutions Trusteee Ltd

15.00M

0.74%

-262.98K

-1.72%

Jun 30, 2025

Fidelity Institutional Asset Management

9.53M

0.47%

+10.84K

+0.11%

Jun 30, 2025

T. Rowe Price International Ltd

8.05M

0.4%

+324.11K

+4.20%

Jun 30, 2025

RBC Capital Markets Wealth Management

6.99M

0.34%

+740.61K

+11.84%

Jun 30, 2025

State Street Investment Management (US)

6.71M

0.33%

-258.77K

-3.71%

Jun 30, 2025

Goldman Sachs Asset Management, L.P.

6.12M

0.3%

-2.36M

-27.84%

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

VanEck Pharmaceutical ETF

4.38%

The Opal International Dividend Income ETF

3.62%

Sound Equity Dividend Income ETF

3.35%

Keating Active ETF

3.28%

USCF Dividend Income Fund

3.26%

Brandes International ETF

2.65%

Altrius Global Dividend ETF

2.27%

Fidelity Blue Chip Value ETF

1.44%

Fidelity Women's Leadership ETF

1.08%

Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF

0.9%

VanEck Pharmaceutical ETF

Proportion4.38%

The Opal International Dividend Income ETF

Proportion3.62%

Sound Equity Dividend Income ETF

Proportion3.35%

Keating Active ETF

Proportion3.28%

USCF Dividend Income Fund

Proportion3.26%

Brandes International ETF

Proportion2.65%

Altrius Global Dividend ETF

Proportion2.27%

Fidelity Blue Chip Value ETF

Proportion1.44%

Fidelity Women's Leadership ETF

Proportion1.08%

Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF

Proportion0.9%

Dividend



A total of 20.79B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 05, 2025

GSK.NB Approximate interim Cash Dividend of gross USD 0.400652 paid on Apr 10, 2025 going ex on Feb 21, 2025

Feb 21, 2025

Apr 10, 2025

Feb 21, 2025

Oct 30, 2024

GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024

Nov 15, 2024

Jan 09, 2025

Nov 15, 2024

Jul 31, 2024

GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Oct 10, 2024

Aug 16, 2024

May 01, 2024

GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024

May 17, 2024

Jul 11, 2024

May 16, 2024

Feb 01, 2024

GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024

Feb 23, 2024

Apr 11, 2024

Feb 22, 2024

Nov 01, 2023

GSK.NB Final Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023

Nov 17, 2023

Jan 11, 2024

Nov 16, 2023

Jul 26, 2023

GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Oct 12, 2023

Aug 17, 2023

Apr 26, 2023

GSK.NB Interim Cash Dividend of gross USD 0.360944 paid on Jul 13, 2023 going ex on May 18, 2023

May 19, 2023

Jul 13, 2023

May 18, 2023

Feb 01, 2023

GSK.NB Interim Cash Dividend of gross USD 0.341883 paid on Apr 13, 2023 going ex on Feb 23, 2023

Feb 24, 2023

Apr 13, 2023

Feb 23, 2023

Nov 02, 2022

GSK.NB Final Cash Dividend of gross USD 0.334785 paid on Jan 12, 2023 going ex on Nov 17, 2022

Nov 18, 2022

Jan 12, 2023

Nov 17, 2022

Stock Split



Date

Type

Ratio

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Date

Type

Ratio

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4

Jun 24, 2022

Merger

5→4